REQUEST A DEMO
Total
USD $0.00
Search more companies

Medison Pharma Lithuania UAB (Lithuania)

Main Activities: Research and Development in the Social Sciences and Humanities | Marketing Research and Public Opinion Polling
Full name: Medison Pharma Lithuania UAB Profile Updated: January 01, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Russian Download a sample report

Medison Pharma Lithuania UAB is an enterprise in Lithuania, with the main office in Kaunas. The company operates in the Research and Development in the Social Sciences and Humanities sector. It was established on February 12, 2021. The total number of employees is currently 9 (2025). The latest financial highlights indicate a net sales revenue increase of 36.14% in 2024. The enterprise’s net profit margin increased by 0.27% in 2024.

Headquarters
Uznerio g. 1-2
Kaunas; Kaunas County; Postal Code: LT-47484

Contact Details: Purchase the Medison Pharma Lithuania UAB report to view the information.

Basic Information
Total Employees:
Purchase the Medison Pharma Lithuania UAB report to view the information.
Registered Capital:
Purchase the Medison Pharma Lithuania UAB report to view the information.
Financial Auditors:
Purchase the Medison Pharma Lithuania UAB report to view the information.
Incorporation Date:
February 12, 2021
Key Executives
Purchase this report to view the information.
Member of the Management Board
Company Performance
Financial values in the chart are available after Medison Pharma Lithuania UAB report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
36.14%
Total operating revenue
36.14%
Net Profit (Loss) for the Period
45.71%
Total equity
66.39%
Net Profit Margin
0.27%
Return on Equity (ROE)
-5.66%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?